LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular, Inc. disclosed that a director acquired common stock through the vesting of equity-based awards on 12/12/2025. Two transactions converted derivative awards into common stock, each for 5 shares of common stock at a price of $0 per share under transaction code "M," which typically reflects the exercise or conversion of derivative securities.
The new shares came from the release of dividend equivalent rights that were tied to restricted stock unit and performance stock unit awards originally granted on 12/12/2022. Each dividend equivalent right was the economic equivalent of one share of LeMaitre Vascular common stock, and any fractional shares were settled in cash, leaving no remaining dividend equivalent rights outstanding after these vesting events.
A LeMaitre Vascular director reported automatic share acquisitions tied to existing equity awards. On 12/12/2025, dividend equivalent rights linked to stock awards converted into common shares at an exercise price of $0, with the transactions coded as exercises (code M). The director received 5 shares from dividend equivalent rights associated with a restricted stock unit award granted on 12/12/2022 and another 5 shares from rights linked to a performance stock unit award granted on the same date. Fractional shares from these rights, if any, were settled in cash, leaving a remaining balance of 0 dividend equivalent rights.
A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025. The director acquired 5 shares of common stock in each of two transactions at a price of $0 per share, reflecting the release of dividend equivalent rights on a one-for-one basis into common stock.
Following these transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock directly. The derivative positions shown were dividend equivalent rights linked to restricted stock unit and performance stock unit awards granted on 12/12/2022, each right being the economic equivalent of one share. After vesting, the number of these derivative rights was reduced to zero, with any fractional shares settled in cash.
LeMaitre Vascular director Lawrence J. Jasinski reported the release and exercise of dividend equivalent rights on 2025-12-12, converting those rights into 10 shares of common stock at $0.0000 per share in connection with vesting of 2022 restricted and performance stock unit awards. Fractional share amounts, if any, were settled in cash, leaving no remaining dividend equivalent rights. Following these transactions, he directly holds 5,322 shares of common stock.
LeMaitre Vascular director John A. Roush exercised dividend equivalent rights on 12/12/2025, converting a total of 10 rights into an equal number of common shares at $0.0000 per share. After these conversions he holds 3,465 LMAT shares directly and 181.0000 shares indirectly through his spouse. Footnotes explain that these rights were released upon vesting of restricted and performance stock unit awards granted on 12/12/2022, with any fractional rights settled in cash.
LeMaitre Vascular reported an equity grant to its Senior Vice President of Operations. On 12/10/2025, the executive received 1,177 shares of common stock as a restricted stock unit award at a stated price of $0, bringing direct beneficial ownership of common stock to 4,660 shares.
The executive also received a stock option covering 7,222 shares of common stock at an exercise price of $83.66 per share, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over the following three years, and the issuer may withhold shares to satisfy tax obligations. The option vests over four years, with 25% vesting on the first anniversary of the grant date and the balance in equal annual installments over the next three years.
LeMaitre Vascular Inc's chief financial officer reported receiving new equity awards in the company’s stock. On 12/10/2025, the officer acquired 1,177 shares of common stock at a stated price of $0, bringing direct ownership to 2,398 common shares.
The filing also shows a new stock option grant for 7,222 shares with an exercise price of $83.66 and an expiration date of 12/10/2032. The 1,177-share award is structured as restricted stock units that vest 25% on 12/1/2026, with the rest vesting in equal annual installments over the following three years. The option vests over four years at 25% on the first anniversary of the grant date listed, with the balance vesting in equal annual installments over the next three years.
LeMaitre Vascular Inc. disclosed that its president and director received new equity awards. On 12/10/2025, the insider acquired 1,694 shares of common stock as a restricted stock unit award at a price of $0, bringing total common stock beneficially owned to 23,091 shares held directly.
The insider was also granted a stock option for 10,400 shares of common stock with an exercise price of $83.66, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over three years, and include share withholding to cover taxes. The option vests 25% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following three years.
LeMaitre Vascular Inc reported that a company director received new equity awards in the form of common stock and stock options. On 12/10/2025, the director acquired 533 shares of common stock through a restricted stock unit award at a price of $0 per share, bringing direct beneficial ownership to 62,340 shares.
The disclosure also shows stock options covering 3,431 shares of common stock with an exercise price of $83.66 and an expiration date of 12/10/2030. The restricted stock units vest 33 1/3% on 12/1/2026, with the remainder vesting in equal annual installments over the next two years, while the options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following two years.
LeMaitre Vascular reported that one of its directors received new equity awards. On 12/10/2025 the director was granted 533 restricted stock units of common stock at a price of $0 and 3,431 stock options with an exercise price of $83.66 per share.
The restricted stock units vest 33 1/3% on 12/1/2026, with the rest vesting in equal annual installments over the following two years. The options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the remaining two years, and expire on 12/10/2030. After this grant, the director beneficially owns 3,455 common shares directly, 181 shares indirectly through a spouse, and 3,431 options.